2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

SEARCH RESULTS

BROWSE BY PROGRAM

Discover abstracts and sessions by meeting track.

Search Criteria: Program: Oral Abstract Session
182 Sessions
Saturday, December 12, 2026 76 Sessions
09:30 a.m. - 11:00 a.m. 112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics Program: Oral Abstract Session
Location

MCCNO - 243-245

09:30 a.m. - 11:00 a.m. 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Natural history Program: Oral Abstract Session
Location

MCCNO - 252-254

09:30 a.m. - 11:00 a.m. 201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation Program: Oral Abstract Session
Location

MCCNO - 291-292

09:30 a.m. - 11:00 a.m. 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Bench to Bedside: Practical Applications in ITP Program: Oral Abstract Session
Location

MCCNO - 217-219

09:30 a.m. - 11:00 a.m. 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Refining Risk in Cancer-Associated Thrombosis: From Circulating Biomarkers to Population Outcomes Program: Oral Abstract Session
Location

MCCNO - 208-210

09:30 a.m. - 11:00 a.m. 508. Bone Marrow Failure: Acquired: The Science Behind the Clinic Program: Oral Abstract Session
Location

MCCNO - 295-296

09:30 a.m. - 11:00 a.m. 603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation Program: Oral Abstract Session
Location

MCCNO - 275-277

Description

Transcriptional and epigenetic remodelling orchestrate immune evasion and create therapeutic vulnerabilities in lymphoid malignancies, by providing lineage platicity and competitive fitness, inducing extracellular vesicles secretion to modulate the immune microenvironment, downregulating endogenous retroelements, and reorganizing enhancer condensates.

09:30 a.m. - 11:00 a.m. 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrated Omics Approaches for Precision Medicine in Acute Lymphoblastic Leukemia Program: Oral Abstract Session
Location

MCCNO - 265-268

09:30 a.m. - 11:00 a.m. 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Novel Combination Regimens for Fit and Less-fit AML Patients Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

09:30 a.m. - 11:00 a.m. 617. Acute Myeloid Leukemias: Commercially Available Therapies: Rewriting the AML Playbook: Precision, Intensification, and New Therapeutic Frontiers Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

09:30 a.m. - 11:00 a.m. 621. Lymphomas: Translational – Molecular and Genetic: Genomics and Liquid Biopsy in Lymphoma: Tumor Biology to Clinical Monitoring Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

09:30 a.m. - 11:00 a.m. 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Combinations Move Beyond Chemotherapy Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

09:30 a.m. - 11:00 a.m. 629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Response-Adapted Strategies in Aggressive Lymphomas Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

09:30 a.m. - 11:00 a.m. 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: CALR and Friends: Adventures in MPN! Program: Oral Abstract Session
Location

MCCNO - R02-R05

09:30 a.m. - 11:00 a.m. 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Biomarkers, Resistance, and the Molecular Frontier Program: Oral Abstract Session
Location

MCCNO - Hall B

09:30 a.m. - 11:00 a.m. 636. Myelodysplastic Syndromes: Basic and Translational: Multi-Modal Mapping of Clonal Evolution and Microenvironmental Remodeling in MDS and Leukemic Progression Program: Oral Abstract Session
Location

MCCNO - Hall C

09:30 a.m. - 11:00 a.m. 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches for Patients with Relapsed/Refractory CLL, Richter Transformation, and Hypogammaglobulinemia Program: Oral Abstract Session
Location

MCCNO - 260-262

09:30 a.m. - 11:00 a.m. 654. Multiple Myeloma: Pharmacologic Therapies Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

09:30 a.m. - 11:00 a.m. 655. Multiple Myeloma: Cellular Therapies: CART in Myeloma: Racing Towards a Cure Program: Oral Abstract Session
Location

MCCNO - Hall E

Description

Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel CAR-T constructs, emerging targets beyond BCMA and next-generation platforms designed to improve efficacy and durability.  Presenters will explore how these advances are reshaping treatment paradigms from heavily pretreated myeloma to earlier integration and newly diagnosed treatment settings as the field pushes towards deeper and more durable responses.  Attendees will get insights into latest clinical trial results in this innovative session.

09:30 a.m. - 11:00 a.m. 701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation II Program: Oral Abstract Session
Location

MCCNO - 353-355

09:30 a.m. - 11:00 a.m. 702. CAR-T Cell Therapies: Basic and Translational Program: Oral Abstract Session
Location

MCCNO - 343-345

09:30 a.m. - 11:00 a.m. 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Conditioning the Outcome: Optimizing Transplantation in Acute Leukemia Program: Oral Abstract Session
Location

MCCNO - 388-390

Description

Before and After: Optimizing Conditioning and Maintenance in HCT

09:30 a.m. - 11:00 a.m. 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Cells to Code: AI and the Next Generation of Hematologic Diagnostics Program: Oral Abstract Session
Location

MCCNO - 393-396

Description

This session explores how artificial intelligence, advanced molecular technologies, and innovative model systems are transforming hematologic diagnostics and precision medicine. Presentations span AI-enabled digital pathology and CBC-based immune profiling, rapid genomic testing in AML, computational prediction of cancer immunogenicity, and emerging platforms for therapeutic response testing—highlighting the evolution from traditional morphology and molecular assays toward integrated, data-driven diagnostics.

09:30 a.m. - 11:00 a.m. 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health Program: Oral Abstract Session
Location

MCCNO - 271-273

09:30 a.m. - 11:00 a.m. 907. Outcomes Research: Plasma Cell Disorders - Beyond Disease Control: Supportive Care, Survivorship, and Patient-Centered Outcomes in Multiple Myeloma Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

12:00 p.m. - 01:30 p.m. 401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes Program: Oral Abstract Session
Location

MCCNO - 220-222

Description

Transfusion medicine is rapidly evolving from the delivery of standardized blood products toward precision, data-driven therapies tailored to individual patients and clinical contexts. This session highlights cutting-edge advances spanning the continuum of transfusion care. Topics range from optimizing stem cell mobilization and red cell exchange in patients with sickle cell disease, to reducing alloimmunization through precision antigen matching, improving hemostatic management in cardiac surgery, uncovering the biological effects of platelet transfusions on the developing brain, and developing next-generation recombinant oxygen-carrying blood substitutes. Together, these presentations demonstrate how innovations in transfusion science are improving the safety, effectiveness, and sustainability of blood therapies while laying the foundation for future alternatives to donor-derived blood.

12:00 p.m. - 01:30 p.m. 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma Program: Oral Abstract Session
Location

MCCNO - 278-282

12:00 p.m. - 01:30 p.m. 904. Outcomes Research: Hemoglobinopathies: Health Systems, Care Delivery, and Real-World Outcomes in Sickle Cell Disease Program: Oral Abstract Session
Location

MCCNO - 243-245

02:00 p.m. - 03:30 p.m. 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: The Tip of the Iceberg - How Do We Spot and Stop Organ Damage in Sickle Cell Disease? Program: Oral Abstract Session
Location

MCCNO - 243-245

02:00 p.m. - 03:30 p.m. 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological Program: Oral Abstract Session
Location

MCCNO - 208-210

02:00 p.m. - 03:30 p.m. 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: New Frontiers in Thrombosis: FXI Inhibition, Intervention, and Long-term Outcomes Program: Oral Abstract Session
Location

MCCNO - 217-219

02:00 p.m. - 03:30 p.m. 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Mechanisms in Hematopoietic Stem Cell Regulation, Development, and Regeneration Program: Oral Abstract Session
Location

MCCNO - 291-292

02:00 p.m. - 03:30 p.m. 503. Clonal Hematopoiesis, Aging, and Inflammation: Evolution, Interactions, and Interception Program: Oral Abstract Session
Location

MCCNO - Hall E

02:00 p.m. - 03:30 p.m. 506. Bone Marrow Microenvironment Program: Oral Abstract Session
Location

MCCNO - 295-296

02:00 p.m. - 03:30 p.m. 602. Myeloid Oncogenesis: Basic Program: Oral Abstract Session
Location

MCCNO - R06-R09

02:00 p.m. - 03:30 p.m. 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrating Genomic and Functional Approaches to Uncover Mechanisms of Pathogenesis and Treatment Resistance in B-ALL Program: Oral Abstract Session
Location

MCCNO - 265-268

02:00 p.m. - 03:30 p.m. 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis Program: Oral Abstract Session
Location

MCCNO - Hall C

02:00 p.m. - 03:30 p.m. 622. Lymphomas: Translational: Non-Genetic – Lymphoma Landscapes: Spatial Biology of Tumor States and Immune Niches Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

02:00 p.m. - 03:30 p.m. 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Mapping the Post-BTK Inhibitor Landscape: Cellular Therapy, Novel Combinations, and Genomic Insights in B-Cell Lymphomas Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

02:00 p.m. - 03:30 p.m. 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN Program: Oral Abstract Session
Location

MCCNO - Hall B

02:00 p.m. - 03:30 p.m. 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

02:00 p.m. - 03:30 p.m. 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Improving Outcomes for Relapsed/Refractory CLL/SLL Program: Oral Abstract Session
Location

MCCNO - 271-273

Description

Improving outcomes for relapsed/refractory CLL/SLL

02:00 p.m. - 03:30 p.m. 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Clinical Trials for Plasma Cell Dyscrasias and Related Disorders Program: Oral Abstract Session
Location

MCCNO - 278-282

02:00 p.m. - 03:30 p.m. 654. Multiple Myeloma: Pharmacologic Therapies: Novel Approaches in Relapsed Myeloma: Immunotherapies and Small Molecules Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

02:00 p.m. - 03:30 p.m. 655. Multiple Myeloma: Cellular Therapies: Efficacy Meets Safety: Optimizing CART in MM Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

Description

Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel approaches to improve the safety and efficacy of CAR-T products in the clinic. Presenters will explore how new strategies are changing the efficacy and safety balance to reshape treatment paradigms as the field pushes towards deeper and more durable responses. Attendees will get insights into latest clinical data in this important session.

02:00 p.m. - 03:30 p.m. 702. CAR-T Cell Therapies: Basic and Translational: Engineering CAR T-cells for Improved Persistence, Activity, and Tumor Control Program: Oral Abstract Session
Location

MCCNO - 343-345

02:00 p.m. - 03:30 p.m. 703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Expanding the Garage: Advancements in Non-T Cell CAR Platforms and Optimization Strategies Program: Oral Abstract Session
Location

MCCNO - 353-355

02:00 p.m. - 03:30 p.m. 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Building a Better Transplant: Refining the PTCy Platform and Beyond Program: Oral Abstract Session
Location

MCCNO - 388-390

02:00 p.m. - 03:30 p.m. 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Algorithms to the Clinic: AI and Molecular Innovation in Hematology Program: Oral Abstract Session
Location

MCCNO - 393-396

02:00 p.m. - 03:30 p.m. 900. Health Services and Quality Improvement: Hemoglobinopathies - Emerging Clinical, Treatment, and Health Services Considerations Across Different Stages of Sickle Cell Care Program: Oral Abstract Session
Location

MCCNO - 252-254

02:00 p.m. - 03:30 p.m. 902. Health Services and Quality Improvement: Lymphoid Malignancies: CAR-T Cell Therapy Program: Oral Abstract Session
Location

MCCNO - 260-262

02:00 p.m. - 03:30 p.m. 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

02:00 p.m. - 03:30 p.m. 908. Outcomes Research: Myeloid Malignancies: Beyond Biology: Social, Environment, and Healthcare Determinants of Outcomes in Myeloid Malignancies Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

04:00 p.m. - 05:30 p.m. 101. Red Cells and Erythropoiesis, Excluding Iron: Internal and External Drivers of Erythroid Development Program: Oral Abstract Session
Location

MCCNO - 291-292

04:00 p.m. - 05:30 p.m. 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics Program: Oral Abstract Session
Location

MCCNO - 243-245

04:00 p.m. - 05:30 p.m. 322. Hemophilia A and B: Clinical and Epidemiological: Transforming Hemophilia Care: Long-term Outcomes, Treatment Transitions, and Innovation Program: Oral Abstract Session
Location

MCCNO - 208-210

04:00 p.m. - 05:30 p.m. 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational Program: Oral Abstract Session
Location

MCCNO - 217-219

04:00 p.m. - 05:30 p.m. 508. Bone Marrow Failure: Acquired: Clinical Data on PNH and SAA Therapeutics Program: Oral Abstract Session
Location

MCCNO - 295-296

04:00 p.m. - 05:30 p.m. 602. Myeloid Oncogenesis: Basic: Transcriptional and Epigenetic Dependencies Program: Oral Abstract Session
Location

MCCNO - R02-R05

04:00 p.m. - 05:30 p.m. 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms - Resistance Mechanisms and New Therapeutic Vulnerabilities in AML Program: Oral Abstract Session
Location

MCCNO - Hall B

04:00 p.m. - 05:30 p.m. 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Molecular Vulnerabilities and Therapeutic Resistance Program: Oral Abstract Session
Location

MCCNO - 271-273

04:00 p.m. - 05:30 p.m. 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL Program: Oral Abstract Session
Location

MCCNO - 265-268

04:00 p.m. - 05:30 p.m. 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding AML Resistance: Cell States, Immune Niches, and Therapeutic Vulnerabilities Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

04:00 p.m. - 05:30 p.m. 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Measures for Measures: New Tools and New Uses for MRD in AML Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

04:00 p.m. - 05:30 p.m. 621. Lymphomas: Translational – Molecular and Genetic: From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

Description

From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas

04:00 p.m. - 05:30 p.m. 622. Lymphomas: Translational – Non-Genetic: Shaping Lymphoma Fate: Oncogenic Programs, Stromal Support, and Immune Failure Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

04:00 p.m. - 05:30 p.m. 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Study Designs and New Immunotherapy Approaches Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

04:00 p.m. - 05:30 p.m. 634. Myeloproliferative Syndromes: Clinical and Epidemiological: MF and SM: Emerging Targets and Treatment Strategies Program: Oral Abstract Session
Location

MCCNO - Hall C

Description

This is a strong session of new therapies for Myelofibrosis and 1 for Mast cell disease. If other clinical MPN session has 1 MF oral trial could move it here, and swap out the SM trial to theirs if makes sense.<br /><br />Sugested Title: <span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">MF and SM: Emerging Targets and Treatment Strategies</span>

04:00 p.m. - 05:30 p.m. 653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Outcomes for Multiple Myeloma, Young and Old Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

04:00 p.m. - 05:30 p.m. 654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

04:00 p.m. - 05:30 p.m. 702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy Program: Oral Abstract Session
Location

MCCNO - 343-345

04:00 p.m. - 05:30 p.m. 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside Program: Oral Abstract Session
Location

MCCNO - 391-392

Description

Optimal dose for haploidentical transplant<br />Better characterizing products for retroviral vector mutations<br />Association of CD39 expression on CAR T-cells with oxidative stress/lipid peroxidation<br />Characterizing CAR T-cells based on LymphoMAP archetype.<br />Optimizing conditions for potency of CAR NK Cells<br />Efficient base gene editing for SCD using the Prodigy

04:00 p.m. - 05:30 p.m. 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury Program: Oral Abstract Session
Location

MCCNO - 388-390

04:00 p.m. - 05:30 p.m. 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation Outcomes: Lymphoid Malignancies, Pediatric Malignancies, and Donor Factors Program: Oral Abstract Session
Location

MCCNO - 278-282

04:00 p.m. - 05:30 p.m. 802. Chemical Biology and Experimental Therapeutics: Leveraging Chemical Biology for Therapeutic Discovery Program: Oral Abstract Session
Location

MCCNO - 353-355

04:00 p.m. - 05:30 p.m. 902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care Program: Oral Abstract Session
Location

MCCNO - 260-262

Sunday, December 13, 2026 46 Sessions
09:30 a.m. - 11:00 a.m. 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Sickle Cell Disease Care on All Fronts Program: Oral Abstract Session
Location

MCCNO - 252-254

09:30 a.m. - 11:00 a.m. 301. Platelets and Megakaryocytes: Basic and Translational: Megakaryocytes and Platelets from Development to Defense Program: Oral Abstract Session
Location

MCCNO - 208-210

Description

This program is top science that showcases hot topics in platelet and megakaryocyte biology. It is balanced between both platelets and megakaryocytes and also a a broad array of topics. Male to Female representation was difficult, but we currently have one woman. Our first alternate is a woman and we suggest having woman moderators (we suggested two junior and two more senior).<br /><br />abs26-7483 was not chosen for an oral presentation due to concerns about lack of key information in the abstract that didn't allow the group to discern the impact of the findings.<br /><br />Backups<br />1. abs26-10358<br />2. abs26-13313<br />3. abs26-1646

09:30 a.m. - 11:00 a.m. 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Hemorrhage in Hematologic Malignancy: From CAR T-Cells to Clonal Hematopoiesis Program: Oral Abstract Session
Location

MCCNO - 217-219

09:30 a.m. - 11:00 a.m. 503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection Program: Oral Abstract Session
Location

MCCNO - 291-292

09:30 a.m. - 11:00 a.m. 603. Lymphoid Oncogenesis: Basic: Metabolic and Immune Mechanisms Program: Oral Abstract Session
Location

MCCNO - 260-262

Description

Mechanisms of adaptation to intrinsic metabolic and proteostatic stress during normal hematopoiesis and malignant transformation include induction of chronic endoplasmic reticulum stress, rewiring of tRNA modifications and metabolic precursor transporters, and aberrant activation of metabolic programs downstream of cell surface molecules, creating lineage-specific targetable dependencies in lymphoid malignancies.

09:30 a.m. - 11:00 a.m. 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Prognostic and Predictive Factors in AML and BPDCN Program: Oral Abstract Session
Location

MCCNO - Hall B

09:30 a.m. - 11:00 a.m. 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Emerging Clinically Relevant Biomarkers in AML Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

09:30 a.m. - 11:00 a.m. 621. Lymphomas: Translational – Molecular and Genetic Program: Oral Abstract Session
Location

MCCNO - 275-277

09:30 a.m. - 11:00 a.m. 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Emerging Targeted Therapies in NK/T-Cell Lymphomas and HLH: From Epigenetic Modulation to JAK Signaling Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

09:30 a.m. - 11:00 a.m. 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Evaluation of Newly-Diagnosed DLBCL Patients Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

09:30 a.m. - 11:00 a.m. 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis Program: Oral Abstract Session
Location

MCCNO - R02-R05

09:30 a.m. - 11:00 a.m. 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Targeted Agents and Combination Regimens in CMML, MDS, and MDS/MPN Overlap Neoplasms: Emerging Clinical Trial Data Program: Oral Abstract Session
Location

MCCNO - Hall C

Description

This session surveys the latest early-phase clinical data shaping the treatment landscape for chronic myelomonocytic leukemia (CMML), higher-risk myelodysplastic syndromes (MDS), and MDS/MPN overlap disorders. Presentations span first-in-human results for a novel CCR2-targeting cytotoxicity chimera, combination regimens pairing hypomethylating agents with venetoclax and other cytotoxic or immune-targeting partners (anti-CD47, anti-IL1RAP), and an all-oral treatment approach for MDS/MPN overlap syndromes. A pediatric-focused study extends the discussion to secondary myeloid neoplasms. Together, these studies reflect the field's ongoing shift toward targeted and combination-based strategies aimed at improving outcomes across this heterogeneous group of hard-to-treat myeloid malignancies.

09:30 a.m. - 11:00 a.m. 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Studies in Previously Untreated CLL/SLL Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

Description

TITLE: Studies in previously untreated CLL/SLL

09:30 a.m. - 11:00 a.m. 653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Sequencing and Toxicity Management With Novel Myeloma Therapies Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

09:30 a.m. - 11:00 a.m. 656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: The Evolving Landscape of Risk Definition in Multiple Myeloma Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

09:30 a.m. - 11:00 a.m. 702. CAR-T Cell Therapies: Basic and Translational: Next-Generation CAR T-cell Therapy Strategies for AML Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

09:30 a.m. - 11:00 a.m. 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities Program: Oral Abstract Session
Location

MCCNO - 343-345

09:30 a.m. - 11:00 a.m. 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT Program: Oral Abstract Session
Location

MCCNO - 388-390

09:30 a.m. - 11:00 a.m. 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and Preventing Post-transplant Relapse and GvHD: Minimal Residual Disease, Immune Dynamics, and Biomarkers Program: Oral Abstract Session
Location

MCCNO - 353-355

09:30 a.m. - 11:00 a.m. 900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings Program: Oral Abstract Session
Location

MCCNO - 243-245

09:30 a.m. - 11:00 a.m. 902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care Program: Oral Abstract Session
Location

MCCNO - 271-273

12:00 p.m. - 01:30 p.m. 101. Red Cells and Erythropoiesis, Excluding Iron: Programming Erythropoiesis: From Chromatin Architecture to Red Cell Fate Program: Oral Abstract Session
Location

MCCNO - 291-292

12:00 p.m. - 01:30 p.m. 321. Coagulation and Fibrinolysis: Basic and Translational: Right Protein, Right Place: Compartmentalized Coagulation in Development, Vasculature, and Organ Injury Program: Oral Abstract Session
Location

MCCNO - 220-222

Description

Coagulation and fibrinolytic proteins are defined by the clot, but their biology extends well past it. This session assembles six studies showing that what a hemostatic protein does is context-dependent. Talks span a deep mutational stability map of tissue factor validated in human population data; rescue genetics dissecting which TFPI activities are indispensable for embryonic development; conditional deletion revealing that endothelial and hepatic stellate cell ADAMTS13 are functionally non-redundant; integrin β1–dependent FVIII signaling that preserves cerebral microvascular integrity; protection from renal fibrosis in FXII and uPAR deficiency; and a murine platform that reproduces human acute obstetric coagulopathy and its response to tranexamic acid.

12:00 p.m. - 01:30 p.m. 322. Hemophilia A and B: Clinical and Epidemiological: Precision Hemophilia Care: Bleeding Prediction and Overcoming Inhibitors Program: Oral Abstract Session
Location

MCCNO - 217-219

12:00 p.m. - 01:30 p.m. 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies Program: Oral Abstract Session
Location

MCCNO - 295-296

12:00 p.m. - 01:30 p.m. 628. Aggressive Lymphomas: Cellular Therapies: Optimizing Every Step of the CAR T-Cell Journey in Large B-Cell Lymphoma Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

12:00 p.m. - 01:30 p.m. 629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Clinical Trials in Untreated and Relapsed/Refractory LBCL, Including CNS Lymphoma Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

12:00 p.m. - 01:30 p.m. 656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Tracking MRD in Blood and Marrow of Multiple Myeloma Patients Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

12:00 p.m. - 01:30 p.m. 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My! Program: Oral Abstract Session
Location

MCCNO - 243-245

12:00 p.m. - 01:30 p.m. 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias Program: Oral Abstract Session
Location

MCCNO - 208-210

12:00 p.m. - 01:30 p.m. 907. Outcomes Research: Plasma Cell Disorders: T-Cell–Redirecting Therapies in Multiple Myeloma: Treatment Optimization and Emerging Toxicities Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

12:00 p.m. - 01:30 p.m. 909. Medical Education and Workforce Development: Shaping the Future: From AI to Wellbeing and the Hematology Workforce Program: Oral Abstract Session
Location

MCCNO - 293-294

04:30 p.m. - 06:00 p.m. 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Strategies and Modulation of Anti-Tumor Responses Program: Oral Abstract Session
Location

MCCNO - 260-262

04:30 p.m. - 06:00 p.m. 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors Program: Oral Abstract Session
Location

MCCNO - Hall B

04:30 p.m. - 06:00 p.m. 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Genetic Heterogeneity and Functional Vulnerabilities in AML Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

04:30 p.m. - 06:00 p.m. 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Triple S: MPN Goes Spatial, Selective and to the Cell Surface! Program: Oral Abstract Session
Location

MCCNO - Hall C

04:30 p.m. - 06:00 p.m. 641. Chronic Lymphocytic Leukemia: Basic and Translational: Resolving Complexity of CLL and Richter Transformation Program: Oral Abstract Session
Location

MCCNO - 265-268

04:30 p.m. - 06:00 p.m. 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Optimizing T-cell Redirected Therapy for Myeloma and Related Conditions Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

04:30 p.m. - 06:00 p.m. 656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Immune and Microenvironment Drivers of Treatment Outcomes in Multiple Myeloma Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

04:30 p.m. - 06:00 p.m. 701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I Program: Oral Abstract Session
Location

MCCNO - 343-345

04:30 p.m. - 06:00 p.m. 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

04:30 p.m. - 06:00 p.m. 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Long-term Follow-up After Allogeneic Hematopoietic Cell Transplantation Program: Oral Abstract Session
Location

MCCNO - 388-390

04:30 p.m. - 06:00 p.m. 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation for Myeloid Malignancies: Timing, Donors, and Disease Control Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

04:30 p.m. - 06:00 p.m. 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology Program: Oral Abstract Session
Location

MCCNO - 252-254

04:30 p.m. - 06:00 p.m. 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Outcomes Across the Age Spectrum: Assessment, Tolerability, and Survivorship Program: Oral Abstract Session
Location

MCCNO - 278-282

04:30 p.m. - 06:00 p.m. 908. Outcomes Research: Myeloid Malignancies: From Patient Voice to Clinical Impact: PROs and Real-World Outcomes in an Evolving Digital Era Program: Oral Abstract Session
Location

MCCNO - R06-R09

Monday, December 14, 2026 60 Sessions
10:30 a.m. - 12:00 p.m. 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: End-organ Dysfunction in Sickle Cell Disease: From Risk Prediction to Therapeutic Innovation Program: Oral Abstract Session
Location

MCCNO - 252-254

10:30 a.m. - 12:00 p.m. 201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology Program: Oral Abstract Session
Location

MCCNO - 291-292

10:30 a.m. - 12:00 p.m. 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Reshaping the Research Frontier in ITP: Targeted Therapeutics and Validation of the ITP Diagnosis Program: Oral Abstract Session
Location

MCCNO - 217-219

10:30 a.m. - 12:00 p.m. 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

10:30 a.m. - 12:00 p.m. 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: New Genomic and Immunologic Insights Program: Oral Abstract Session
Location

MCCNO - 265-268

10:30 a.m. - 12:00 p.m. 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Treatment Decisions for Acute Myeloid Leukemia in Pediatric and AYA Patients Program: Oral Abstract Session
Location

MCCNO - R02-R05

10:30 a.m. - 12:00 p.m. 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel Immunotherapeutic Approaches to AML Program: Oral Abstract Session
Location

MCCNO - Hall C

10:30 a.m. - 12:00 p.m. 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Finite vs. Forever: Redefining Treatment Duration in Relapsed/Refractory Waldenstrom’s Macroglobulinemia and Marginal Zone Lymphoma Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

10:30 a.m. - 12:00 p.m. 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Precision Approaches in NK/T-Cell Lymphoma and CTCL: Optimizing Therapy and Predicting Outcomes Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

10:30 a.m. - 12:00 p.m. 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

10:30 a.m. - 12:00 p.m. 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: New Drugs, New Paradigms in CML Program: Oral Abstract Session
Location

MCCNO - R06-R09

10:30 a.m. - 12:00 p.m. 637. Myelodysplastic Syndromes: Clinical and Epidemiological Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

10:30 a.m. - 12:00 p.m. 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Initial CLL Treatment Strategies with Targeted Agent Combinations and MRD-guidance Program: Oral Abstract Session
Location

MCCNO - 271-273

10:30 a.m. - 12:00 p.m. 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Transcriptional and Epigenetic Control of MM Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

10:30 a.m. - 12:00 p.m. 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis Program: Oral Abstract Session
Location

MCCNO - 260-262

10:30 a.m. - 12:00 p.m. 702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety Program: Oral Abstract Session
Location

MCCNO - 353-355

10:30 a.m. - 12:00 p.m. 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution Program: Oral Abstract Session
Location

MCCNO - 388-390

10:30 a.m. - 12:00 p.m. 907. Outcomes Research: Plasma Cell Disorders: Real-World Efficacy of Immunotherapy Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

Description

Efficacy of T cell engagers and anti-CD38 therpies in real world studies

10:30 a.m. - 12:00 p.m. 908. Outcomes Research: Myeloid Malignancies: Advancing Precision and Value-Based Care in AML: Real-World Evidence Across the Disease Continuum Program: Oral Abstract Session
Location

MCCNO - Hall B

02:45 p.m. - 04:15 p.m. 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Iron at the Crossroads: Physiology, Pathology, Including Pregnancy Program: Oral Abstract Session
Location

MCCNO - 291-292

02:45 p.m. - 04:15 p.m. 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Red Cell Rescue: Novel Approaches in Sickle Cell Disease Program: Oral Abstract Session
Location

MCCNO - 243-245

02:45 p.m. - 04:15 p.m. 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation Program: Oral Abstract Session
Location

MCCNO - R06-R09

02:45 p.m. - 04:15 p.m. 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: New Therapeutics in ITP and Chemotherapy-Induced Thrombocytopenia Program: Oral Abstract Session
Location

MCCNO - 217-219

02:45 p.m. - 04:15 p.m. 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological Program: Oral Abstract Session
Location

MCCNO - 220-222

02:45 p.m. - 04:15 p.m. 602. Myeloid Oncogenesis: Basic: Rewiring Chromatin, Metabolism, and Immunity in Myeloid Neoplasms Program: Oral Abstract Session
Location

MCCNO - R02-R05

02:45 p.m. - 04:15 p.m. 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, Genomic, and Social Predictors of Outcomes Program: Oral Abstract Session
Location

MCCNO - 265-268

02:45 p.m. - 04:15 p.m. 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Venetoclax-based Therapy and AML Risk Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

Description

Updates in AML diagnosis, risk factors, and clinical outcomes in the venetoclax era

02:45 p.m. - 04:15 p.m. 617. Acute Myeloid Leukemias: Commercially Available Therapies: Molecularly Targeted Combinations in AML Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

02:45 p.m. - 04:15 p.m. 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

02:45 p.m. - 04:15 p.m. 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: From Trials to Reality: Real-World Evidence in Large B-cell Lymphoma Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

02:45 p.m. - 04:15 p.m. 629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: T-cell Engagers and ADC Combinations and Long-Term Outcomes of Trials in Relapsed/Refractory LBCL Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

02:45 p.m. - 04:15 p.m. 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs Program: Oral Abstract Session
Location

MCCNO - Hall B

Description

This partial session is a mix of important abstracts of molecular observations in MPNs and Histiocytic Disorders. Suggested title (After discussion with other Lead reviewer Florian Heidel:  <blockquote type="cite" style="margin: 0px 10px !important; caret-color: #212121; color: #212121; font-family: Aptos; font-size: 16px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-line: none; text-decoration-thickness: auto; text-decoration-style: solid;"> <div> <div> <div style="direction: ltr; font-family: Aptos, Arial, Helvetica, sans-serif; font-size: 12pt;">Molecular Insights and New Approaches in MPNs</div> </div> </div> </blockquote>

02:45 p.m. - 04:15 p.m. 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Genomics Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

02:45 p.m. - 04:15 p.m. 653. Multiple Myeloma: Clinical and Epidemiological: Evolving Population-Level Outcomes and Trends Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

02:45 p.m. - 04:15 p.m. 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence Program: Oral Abstract Session
Location

MCCNO - 353-355

02:45 p.m. - 04:15 p.m. 801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology Program: Oral Abstract Session
Location

MCCNO - 388-390

02:45 p.m. - 04:15 p.m. 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: AI at the Bedside: From Prediction to Therapeutic Decisions Program: Oral Abstract Session
Location

MCCNO - 393-396

Description

This session highlights the transition of AI from diagnostic innovation to clinical decision support and personalized patient management. Presentations demonstrate how AI can predict treatment-related toxicities and complications, identify cardiovascular and bleeding risks, enhance MRD assessment, automate diagnostic triage, and improve disease risk stratification. Together, these studies illustrate the emerging role of AI in anticipating clinical outcomes, guiding therapeutic decisions, and enabling more precise, individualized care in hematologic malignancies.

02:45 p.m. - 04:15 p.m. 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: H and T on the Rocks: Real-World Hemostasis and Thrombosis Program: Oral Abstract Session
Location

MCCNO - 252-254

02:45 p.m. - 04:15 p.m. 907. Outcomes Research: Plasma Cell Disorders: Beyond Response Rates: T-cell Engagement in the Real World Program: Oral Abstract Session
Location

MCCNO - 260-262

Description

Clinical issues with T cell engagers (scheduling, out-patient delivery, CRS prophylaxis, tumor flare, maintenance). One abstarct on bone modifying therapy in myeloma that didn't fit elsewhere.

02:45 p.m. - 04:15 p.m. 908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place Program: Oral Abstract Session
Location

MCCNO - Hall C

04:30 p.m. - 06:00 p.m. 101. Red Cells and Erythropoiesis, Excluding Iron: How to Make a Red Cell: Remodeling, Enucleation, Signaling, and Resilience Program: Oral Abstract Session
Location

MCCNO - 291-292

04:30 p.m. - 06:00 p.m. 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: T and NK Cell Development and Anti-Tumor Functions Program: Oral Abstract Session
Location

MCCNO - R06-R09

04:30 p.m. - 06:00 p.m. 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Program: Oral Abstract Session
Location

MCCNO - Hall B

04:30 p.m. - 06:00 p.m. 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Frontline Therapy in Acute Lymphoblastic Leukemia: At the Crossroads of Chemotherapy, Immunotherapy, and Targeted Therapy Across the Age Spectrum Program: Oral Abstract Session
Location

MCCNO - 265-268

04:30 p.m. - 06:00 p.m. 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Chemotherapy and Transplantation Program: Oral Abstract Session
Location

MCCNO - Great Hall BC

Description

Biomarkers, toxicity, and outcomes with intensive chemotherapy and SCT-based approaches

04:30 p.m. - 06:00 p.m. 617. Acute Myeloid Leukemias: Commercially Available Therapies Program: Oral Abstract Session
Location

MCCNO - Great Hall AD

04:30 p.m. - 06:00 p.m. 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - From Cytotoxic to Selective: The BTK Inhibitor Revolution in The Frontline Treatment of Mantle Cell Lymphoma Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre B

04:30 p.m. - 06:00 p.m. 624. Hodgkin Lymphomas: Clinical and Epidemiological: Precision, Prognostication, and Paradigm Shifts Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre C

04:30 p.m. - 06:00 p.m. 628. Aggressive Lymphomas: Cellular Therapies: Novel CAR-T Constructs, Durability, and Long-Term Outcomes Program: Oral Abstract Session
Location

MCCNO - New Orleans Theatre A

04:30 p.m. - 06:00 p.m. 634. Myeloproliferative Syndromes: Clinical and Epidemiological: ET and PV: Moving Beyond Conventional Therapy Program: Oral Abstract Session
Location

MCCNO - Hall C

Description

This session are outstanding clinical trials in ET and PV. Suggested session title<br /><br /><span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">ET and PV: Moving Beyond Conventional Therapy</span>

04:30 p.m. - 06:00 p.m. 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Basic and Translational Research Program: Oral Abstract Session
Location

MCCNO - La Nouvelle C

04:30 p.m. - 06:00 p.m. 653. Multiple Myeloma: Clinical and Epidemiological: Differentiating Multiple Myeloma(s): A Path to Cure Program: Oral Abstract Session
Location

MCCNO - La Nouvelle A-B

04:30 p.m. - 06:00 p.m. 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Early Innovation of Immune Effector Cell Therapies Program: Oral Abstract Session
Location

MCCNO - 388-390

04:30 p.m. - 06:00 p.m. 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects Program: Oral Abstract Session
Location

MCCNO - 353-355

04:30 p.m. - 06:00 p.m. 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Emerging Technologies for Molecular Classification, Monitoring, and Modelling Program: Oral Abstract Session
Location

MCCNO - 393-396

04:30 p.m. - 06:00 p.m. 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: A World of Bleeding and Clotting Program: Oral Abstract Session
Location

MCCNO - 217-219

04:30 p.m. - 06:00 p.m. 903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing Program: Oral Abstract Session
Location

MCCNO - R02-R05

04:30 p.m. - 06:00 p.m. 904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies Program: Oral Abstract Session
Location

MCCNO - 252-254

04:30 p.m. - 06:00 p.m. 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA Program: Oral Abstract Session
Location

MCCNO - 243-245

04:30 p.m. - 06:00 p.m. 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Assessing Real World Effectiveness and Toxicity of Immune and Cellular Therapies Program: Oral Abstract Session
Location

MCCNO - 260-262